The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages
Standard
The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. / Knipper, Sophie; Pecoraro, Angela; Palumbo, Carlotta; Rosiello, Giuseppe; Luzzago, Stefano; Deuker, Marina; Tian, Zhe; Shariat, Shahrokh F; Saad, Fred; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre I.
in: CANCER CAUSE CONTROL, Jahrgang 31, Nr. 3, 03.2020, S. 283-290.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages
AU - Knipper, Sophie
AU - Pecoraro, Angela
AU - Palumbo, Carlotta
AU - Rosiello, Giuseppe
AU - Luzzago, Stefano
AU - Deuker, Marina
AU - Tian, Zhe
AU - Shariat, Shahrokh F
AU - Saad, Fred
AU - Tilki, Derya
AU - Graefen, Markus
AU - Karakiewicz, Pierre I
PY - 2020/3
Y1 - 2020/3
N2 - PURPOSE: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate cancer (PCa) patients of all stages and across all treatment modalities.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 579,369 PCa patients. Cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used. Subgroup analyses were performed according to ethnicity (African-Americans), clinical stage (T1-2N0M0, T3-4N0M0, TanyN1M0, and TanyNanyM1), as well as treatment modalities.RESULTS: Patient distribution was as follows: 142,338 (24.6%) < 60 years; 113,064 (19.5%) 60-64 years; 127,158 (21.9%) 65-69 years; 94,782 (16.4%) 70-74 years; and 102,027 (17.6%) ≥ 75 years. Older patients harbored worse tumor characteristics and more frequently received no local treatment. Overall, 10-year CSM rates were 4.8, 5.3, 5.9, 7.6, and 14.6%, respectively, in patients aged < 60, 60-64, 65-69, 70-74 ,and ≥ 75 years (p < 0.001). In MCR focusing on the overall cohort and T1-2N0M0 patients, older age independently predicted higher CSM, but not in T3-4N0-1M0-1 patients.CONCLUSIONS: Older age was associated with higher grade and stage and independently predicted higher CSM in T1-2N0M0 patients, but not in higher stages. Differences in diagnostics and therapeutics seem to affect elderly patients within T1-2N0M0 PCa and should be avoided if possible.
AB - PURPOSE: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate cancer (PCa) patients of all stages and across all treatment modalities.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 579,369 PCa patients. Cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used. Subgroup analyses were performed according to ethnicity (African-Americans), clinical stage (T1-2N0M0, T3-4N0M0, TanyN1M0, and TanyNanyM1), as well as treatment modalities.RESULTS: Patient distribution was as follows: 142,338 (24.6%) < 60 years; 113,064 (19.5%) 60-64 years; 127,158 (21.9%) 65-69 years; 94,782 (16.4%) 70-74 years; and 102,027 (17.6%) ≥ 75 years. Older patients harbored worse tumor characteristics and more frequently received no local treatment. Overall, 10-year CSM rates were 4.8, 5.3, 5.9, 7.6, and 14.6%, respectively, in patients aged < 60, 60-64, 65-69, 70-74 ,and ≥ 75 years (p < 0.001). In MCR focusing on the overall cohort and T1-2N0M0 patients, older age independently predicted higher CSM, but not in T3-4N0-1M0-1 patients.CONCLUSIONS: Older age was associated with higher grade and stage and independently predicted higher CSM in T1-2N0M0 patients, but not in higher stages. Differences in diagnostics and therapeutics seem to affect elderly patients within T1-2N0M0 PCa and should be avoided if possible.
U2 - 10.1007/s10552-020-01273-5
DO - 10.1007/s10552-020-01273-5
M3 - SCORING: Journal article
C2 - 32034540
VL - 31
SP - 283
EP - 290
JO - CANCER CAUSE CONTROL
JF - CANCER CAUSE CONTROL
SN - 0957-5243
IS - 3
ER -